Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111


SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors.

Shorstova T, Marques M, Su J, Johnston J, Kleinman CL, Hamel N, Huang S, Alaoui-Jamali MA, Foulkes WD, Witcher M.

Cancer Res. 2019 May 15;79(10):2761-2774. doi: 10.1158/0008-5472.CAN-18-1545. Epub 2019 Mar 15.


A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.

Chang CH, Bijian K, Wernic D, Su J, da Silva SD, Yu H, Qiu D, Asslan M, Alaoui-Jamali MA.

Autophagy. 2019 Aug;15(8):1376-1390. doi: 10.1080/15548627.2019.1582951. Epub 2019 Mar 1.


TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis.

da Silva SD, Xu B, Maschietto M, Marchi FA, Alkailani MI, Bijian K, Xiao D, Alaoui-Jamali MA.

Mol Cancer Ther. 2019 Jan;18(1):139-146. doi: 10.1158/1535-7163.MCT-17-1261. Epub 2018 Oct 29.


Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer.

Carnielli CM, Macedo CCS, De Rossi T, Granato DC, Rivera C, Domingues RR, Pauletti BA, Yokoo S, Heberle H, Busso-Lopes AF, Cervigne NK, Sawazaki-Calone I, Meirelles GV, Marchi FA, Telles GP, Minghim R, Ribeiro ACP, Brandão TB, de Castro G Jr, González-Arriagada WA, Gomes A, Penteado F, Santos-Silva AR, Lopes MA, Rodrigues PC, Sundquist E, Salo T, da Silva SD, Alaoui-Jamali MA, Graner E, Fox JW, Coletta RD, Paes Leme AF.

Nat Commun. 2018 Sep 5;9(1):3598. doi: 10.1038/s41467-018-05696-2.


Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma.

Rodrigues PC, Sawazaki-Calone I, Ervolino de Oliveira C, Soares Macedo CC, Dourado MR, Cervigne NK, Miguel MC, Ferreira do Carmo A, Lambert DW, Graner E, Daniela da Silva S, Alaoui-Jamali MA, Paes Leme AF, Salo TA, Coletta RD.

Oncotarget. 2017 Aug 19;8(43):74736-74754. doi: 10.18632/oncotarget.20360. eCollection 2017 Sep 26.


MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, Żyłkiewicz E, Mikulski M, Brzózka K, Golas A, Kong Y, Ma M, Huang F, Huor B, Guo Q, da Silva SD, Torres J, Cai Y, Topisirovic I, Su J, Bijian K, Alaoui-Jamali MA, Huang S, Journe F, Ghanem GE, Miller WH Jr, Del Rincón SV.

J Clin Invest. 2017 Nov 1;127(11):4179-4192. doi: 10.1172/JCI91258. Epub 2017 Oct 16.


Meta-analysis of microRNAs expression in head and neck cancer: uncovering association with outcome and mechanisms.

Lubov J, Maschietto M, Ibrahim I, Mlynarek A, Hier M, Kowalski LP, Alaoui-Jamali MA, da Silva SD.

Oncotarget. 2017 Jul 13;8(33):55511-55524. doi: 10.18632/oncotarget.19224. eCollection 2017 Aug 15.


Endosomal sorting and c-Cbl targeting of paxillin to autophagosomes regulate cell-matrix adhesion turnover in human breast cancer cells.

Chang CH, Bijian K, Qiu D, Su J, Saad A, Dahabieh MS, Miller WH Jr, Alaoui-Jamali MA.

Oncotarget. 2017 May 9;8(19):31199-31214. doi: 10.18632/oncotarget.16105.


Design and validation of an orally administrated active L. fermentum-L. acidophilus probiotic formulation using colorectal cancer Apc Min/+ mouse model.

Kahouli I, Malhotra M, Westfall S, Alaoui-Jamali MA, Prakash S.

Appl Microbiol Biotechnol. 2017 Mar;101(5):1999-2019. doi: 10.1007/s00253-016-7885-x. Epub 2016 Nov 11.


Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2.

Saad A, Bijian K, Qiu D, da Silva SD, Marques M, Chang CH, Nassour H, Ramotar D, Damaraju S, Mackey J, Bismar T, Witcher M, Alaoui-Jamali MA.

Sci Rep. 2016 Nov 7;6:36699. doi: 10.1038/srep36699.


Peroxiredoxin 1 interacts with and blocks the redox factor APE1 from activating interleukin-8 expression.

Nassour H, Wang Z, Saad A, Papaluca A, Brosseau N, Affar el B, Alaoui-Jamali MA, Ramotar D.

Sci Rep. 2016 Jul 8;6:29389. doi: 10.1038/srep29389.


microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.

Bakkar A, Alshalalfa M, Petersen LF, Abou-Ouf H, Al-Mami A, Hegazy SA, Feng F, Alhajj R, Bijian K, Alaoui-Jamali MA, Bismar TA.

Mol Biol Rep. 2016 Apr;43(4):229-40. doi: 10.1007/s11033-016-3948-4. Epub 2016 Feb 23.


Predominant Rab-GTPase amplicons contributing to oral squamous cell carcinoma progression to metastasis.

da Silva SD, Marchi FA, Xu B, Bijian K, Alobaid F, Mlynarek A, Rogatto SR, Hier M, Kowalski LP, Alaoui-Jamali MA.

Oncotarget. 2015 Sep 8;6(26):21950-63.


ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.

Alaoui-Jamali MA, Morand GB, da Silva SD.

Front Genet. 2015 Feb 4;6:17. doi: 10.3389/fgene.2015.00017. eCollection 2015. Review.


Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I.

Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, Alaoui-Jamali MA, del Rincon SV, Ashworth T, Roy AL, Emerson BM, Witcher M.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E677-86. doi: 10.1073/pnas.1416674112. Epub 2015 Feb 2.


Epithelial-mesenchymal transition (EMT) markers have prognostic impact in multiple primary oral squamous cell carcinoma.

da Silva SD, Morand GB, Alobaid FA, Hier MP, Mlynarek AM, Alaoui-Jamali MA, Kowalski LP.

Clin Exp Metastasis. 2015 Jan;32(1):55-63. doi: 10.1007/s10585-014-9690-1. Epub 2014 Nov 30.


Insights into genetic and epigenetic determinants with impact on vitamin d signaling and cancer association studies: the case of thyroid cancer.

Morand GB, da Silva SD, Hier MP, Alaoui-Jamali MA.

Front Oncol. 2014 Nov 4;4:309. doi: 10.3389/fonc.2014.00309. eCollection 2014. Review.


Dynamin 2 interacts with connexin 26 to regulate its degradation and function in gap junction formation.

Xiao D, Chen S, Shao Q, Chen J, Bijian K, Laird DW, Alaoui-Jamali MA.

Int J Biochem Cell Biol. 2014 Oct;55:288-97. doi: 10.1016/j.biocel.2014.09.021. Epub 2014 Sep 28.


Neurotherapeutic effects of novel HO-1 inhibitors in vitro and in a transgenic mouse model of Alzheimer's disease.

Gupta A, Lacoste B, Pistell PJ, Ingram DK, Hamel E, Alaoui-Jamali MA, Szarek WA, Vlahakis JZ, Jie S, Song W, Schipper HM.

J Neurochem. 2014 Dec;131(6):778-90. doi: 10.1111/jnc.12927. Epub 2014 Sep 6. Erratum in: J Neurochem. 2014 Dec;131(6):878. Pistel, Paul J [Corrected to Pistell, Paul J].


The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.

Xu B, Teng LH, Silva SD, Bijian K, Al Bashir S, Jie S, Dolph M, Alaoui-Jamali MA, Bismar TA.

Cancer Med. 2014 Feb;3(1):14-24. doi: 10.1002/cam4.168. Epub 2013 Dec 18.


Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread.

Silva SD, Alaoui-Jamali MA, Hier M, Soares FA, Graner E, Kowalski LP.

Clin Exp Metastasis. 2014 Mar;31(3):307-16. doi: 10.1007/s10585-013-9629-y. Epub 2013 Dec 15.


Targeting focal adhesion turnover in invasive breast cancer cells by the purine derivative reversine.

Bijian K, Lougheed C, Su J, Xu B, Yu H, Wu JH, Riccio K, Alaoui-Jamali MA.

Br J Cancer. 2013 Nov 26;109(11):2810-8. doi: 10.1038/bjc.2013.675. Epub 2013 Oct 29.


TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target.

da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, Rogatto SR, Kowalski LP.

Cancer. 2014 Feb 1;120(3):352-62. doi: 10.1002/cncr.28404. Epub 2013 Oct 21.


Total synthesis and biological activity of marine alkaloid Eudistomins Y1-Y7 and their analogues.

Jin H, Zhang P, Bijian K, Ren S, Wan S, Alaoui-Jamali MA, Jiang T.

Mar Drugs. 2013 Apr 29;11(5):1427-39. doi: 10.3390/md11051427.


Recurrent oral cancer: current and emerging therapeutic approaches.

da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA.

Front Pharmacol. 2012 Jul 30;3:149. doi: 10.3389/fphar.2012.00149. eCollection 2012.


Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.

Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU.

Oncogene. 2013 May 16;32(20):2527-33. doi: 10.1038/onc.2012.283. Epub 2012 Jul 16.


Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.

Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA.

Eur J Med Chem. 2012 Feb;48:143-52. doi: 10.1016/j.ejmech.2011.12.006. Epub 2011 Dec 9.


PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.


Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion.

Xu Y, Bismar TA, Su J, Xu B, Kristiansen G, Varga Z, Teng L, Ingber DE, Mammoto A, Kumar R, Alaoui-Jamali MA.

J Exp Med. 2010 Oct 25;207(11):2421-37. doi: 10.1084/jem.20100433. Epub 2010 Oct 11.


A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer.

Alaoui-Jamali MA, Bismar TA, Gupta A, Szarek WA, Su J, Song W, Xu Y, Xu B, Liu G, Vlahakis JZ, Roman G, Jiao J, Schipper HM.

Cancer Res. 2009 Oct 15;69(20):8017-24. doi: 10.1158/0008-5472.CAN-09-0419. Epub 2009 Oct 6.


Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment.

Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S, Alaoui-Jamali MA.

J Proteome Res. 2009 May;8(5):2173-85. doi: 10.1021/pr800979e.


Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.

Darnel AD, Behmoaram E, Vollmer RT, Corcos J, Bijian K, Sircar K, Su J, Jiao J, Alaoui-Jamali MA, Bismar TA.

Clin Cancer Res. 2009 Feb 15;15(4):1376-83. doi: 10.1158/1078-0432.CCR-08-1789.


Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells.

Xu Y, Benlimame N, Su J, He Q, Alaoui-Jamali MA.

Br J Cancer. 2009 Feb 24;100(4):633-43. doi: 10.1038/sj.bjc.6604901. Epub 2009 Feb 3.


Discovery of indoline-based, natural-product-like compounds as probes of focal adhesion kinase signaling pathways.

Poondra RR, Kumar NN, Bijian K, Prakesch M, Campagna-Slater V, Reayi A, Reddy PT, Choudhry A, Barnes ML, Leek DM, Daroszewska M, Lougheed C, Xu B, Schapira M, Alaoui-Jamali MA, Arya P.

J Comb Chem. 2009 Mar 9;11(2):303-9. doi: 10.1021/cc8001525.


Early stage cancer cell invasion: signaling, biomarkers and therapeutic targeting.

Behmoaram E, Bijian K, Bismar TA, Alaoui-Jamali MA.

Front Biosci. 2008 May 1;13:6314-25. Review.


A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma.

Mlynarek AM, Balys RL, Su J, Hier MP, Black MJ, Alaoui-Jamali MA.

Arch Otolaryngol Head Neck Surg. 2007 Sep;133(9):910-8.


Substituted 6-amino-4H-[1,2]dithiolo[4,3-b]pyrrol-5-ones: synthesis, structure-activity relationships, and cytotoxic activity on selected human cancer cell lines.

Li B, Lyle MP, Chen G, Li J, Hu K, Tang L, Alaoui-Jamali MA, Webster J.

Bioorg Med Chem. 2007 Jul 1;15(13):4601-8. Epub 2007 Apr 19.


Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth.

Darwish H, Cho JM, Loignon M, Alaoui-Jamali MA.

Oncogene. 2007 Jun 21;26(29):4319-28. Epub 2007 Jan 29.


Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors.

Alaoui-Jamali MA.

Biomed Pharmacother. 2006 Nov;60(9):629-32. Epub 2006 Aug 28. Review.


Cx26 inhibits breast MDA-MB-435 cell tumorigenic properties by a gap junctional intercellular communication-independent mechanism.

Kalra J, Shao Q, Qin H, Thomas T, Alaoui-Jamali MA, Laird DW.

Carcinogenesis. 2006 Dec;27(12):2528-37. Epub 2006 Jun 15.


A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.

Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, Alaoui-Jamali MA.

Prostate. 2006 Aug 1;66(11):1151-61.


Proteomic technology for biomarker profiling in cancer: an update.

Alaoui-Jamali MA, Xu YJ.

J Zhejiang Univ Sci B. 2006 Jun;7(6):411-20. Review.


FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion.

Benlimame N, He Q, Jie S, Xiao D, Xu YJ, Loignon M, Schlaepfer DD, Alaoui-Jamali MA.

J Cell Biol. 2005 Nov 7;171(3):505-16.


Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.

Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.

Biochem Pharmacol. 2005 Aug 15;70(4):511-9.


Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling.

Alaoui-Jamali MA, Dupré I, Qiang H.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):245-55. Review.


The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.

Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.

J Pharmacol Exp Ther. 2004 Dec;311(3):1163-70. Epub 2004 Sep 9.


The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer.

Chow TY, Alaoui-Jamali MA, Yeh C, Yuen L, Griller D.

Mol Cancer Ther. 2004 Aug;3(8):911-9.


Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells.

Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P, Alaoui-Jamali MA.

Oncogene. 2004 Jul 1;23(30):5252-6.


Supplemental Content

Loading ...
Support Center